ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1769

Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data

Xenofon Baraliakos1, Diego Kyburz2, Jérôme Avouac3, Nick Barkham4 and Soohyun Lee5, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2University Hospital Basel, Basel, Switzerland, 3University of Paris, Paris, France, 4New Cross Hospital, Telford, United Kingdom, 5Celltrion Healthcare, Incheon, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), infliximab, Pharmacoepidemiology, Psoriatic arthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Epidemiology and Public Health Poster III

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: The first subcutaneous (SC) formulation of infliximab (IFX) received approval for the treatment of rheumatoid arthritis (RA), Crohn’s disease (CD), ulcerative colitis (UC), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and psoriasis (PsO) in adults. Pivotal studies of SC IFX (Westhovens R, 2021; Schreiber S, 2021) demonstrated the efficacy and safety of switching from IV to SC IFX for patients with RA, UC and CD.

To improve confidence and uptake for SC IFX, the real-world safety profile continues to be needed. The purpose of the study is to describe and assess adverse events (AEs) associated with SC IFX and IV IFX in all indications using a pharmacovigilance database.

Methods: Data on case reports with SC IFX and IV IFX were obtained from the Celltrion’s global safety database (22 Nov 2019 ~ 7 Feb 2022) since the first launch of SC IFX. AEs reported for SC IFX and IV IFX at the primary system organ class (SOC) level were compared. Disproportionality analysis was conducted. The reporting odds ratio (ROR) and its 95% CI were calculated.

Results: A total of 24,919 AEs were identified. Of these, 604 (2.4%) events for SC IFX and 24,315 (97.6%) events for IV IFX were reported (Table 1).

SC IFX was associated with a low reporting of AEs belonging to the SOCs “Infections and infestations”, “Skin and subcutaneous tissue disorders”, “Musculoskeletal and connective tissue disorders”, “Respiratory, thoracic and mediastinal disorders”, “Vascular disorders” and “Investigations”.

There was a higher reporting probability of SC IFX versus IV IFX for AEs with the SOCs “General disorders and administration site conditions” and “Nervous system disorders”. In each SOC, “injection site reaction (ISR)” and “headache” were most commonly reported. However, most of the AEs were not serious, and no significant difference was found between the two groups in the reporting frequency of serious adverse events (SAE) in both SOCs.

SC IFX showed a lower reporting probability of SAEs in “infection and infestations” and “Gastrointestinal disorders” versus IV IFX. For the remainder of SOCs, no substantial differences were observed.

Disproportionality analyses by indications also showed similar trends (Table 2). Overall, the proportion of SAEs reported by each indication was lower in the SC group (Table 3). The ROR in most SOCs was not significantly different.

Conclusion: In most of the SOCs, the reporting probabilities of AEs and SAEs for SC IFX SC versus IV IFX were found to be lower or similar. This was similar in the analysis by indication.

An increased reporting of AEs for SOC “General disorders and administration site conditions” was observed with SC IFX versus IV IFX, due to the frequent reporting of ISRs in SC IFX. This is expected due to the difference in the route of administration, which is consistent with the results of pivotal clinical trials. Serious ISRs were low in both groups.

Although the characteristics of patients were not balanced and the number of reports collected in the SC group was relatively small, this real-world analysis confirms a comparable safety profile of SC IFX and IV IFX in the licensed indications.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi; D. Kyburz, AbbVie/Abbott, Janssen, Eli Lilly, Novartis, Pfizer, Takeda; J. Avouac, Galapagos, AbbVie, Lilly, Pfizer, Bristol Myers Squibb, Novartis, Fresenius-Kabi, Sanofi, Sandoz, Nordic Pharma, Biogen, Medac, Janssen, Roche-Chugai; N. Barkham, Celltrion Healthcare; S. Lee, Celltrion Healthcare.

To cite this abstract in AMA style:

Baraliakos X, Kyburz D, Avouac J, Barkham N, Lee S. Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/comparative-evaluation-of-adverse-events-associated-with-subcutaneous-infliximab-ct-p13-sc-and-intravenous-infliximab-a-real-world-analysis-of-post-marketing-surveillance-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-evaluation-of-adverse-events-associated-with-subcutaneous-infliximab-ct-p13-sc-and-intravenous-infliximab-a-real-world-analysis-of-post-marketing-surveillance-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology